Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 17/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 17/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430370 | 0.95 | KDM4E (0.51) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL1430272 | 0.89 | KDM4E (0.64) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL1430474 | 0.87 | KDM4E (0.54) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL1430128 | 0.78 | KDM4E (0.56) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL1430908 | 0.73 | KDM4E (0.54) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL18952321 | 0.70 | KCNK3 (0.93) | KCNK3KCNK9 | |
| SCHEMBL1429927 | 0.70 | KDM4E (0.64) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL2227900 | 0.70 | KDM4E (0.67) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL1430403 | 0.70 | KCNK3 (0.48) | KDM4EKCNK3KCNK9GAASLC2A1 | |
| SCHEMBL22364213 | 0.69 | KCNK3 (0.76) | KDM4EKCNK3KCNK9GAASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | KDM4E 3088/4885KCNK3 2486/4885KCNK9 3527/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | KDM4E 3088/4885KCNK3 2486/4885KCNK9 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.